1. U.S. Food and Drug Administration (October 17, 2019). Guidance for industry - patient-reported outcome measures: use in medical product development to support labeling claims. November 30, 2020]; Available from: https://www.fda.gov/media/77832/downloadThis is a complete and concise state of the art review of the KCCQ and its several roles.
2. Kosiborod M, Soto GE, Jones PG, Krumholz HM, Weintraub WS, Deedwania P, et al. Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation. 2007;115(15):1975–81.
3. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation. 2004;110(5):546–51.
4. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150(4):707–15.
5. Virani SS, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596. This reference speaks to the burden of heart failure within our nation and world, highlighting the importance to implement all intervening modalities that will help improve care and outcomes.